CA2488642C - Aryl carbonyl derivatives as glucokinase activators - Google Patents
Aryl carbonyl derivatives as glucokinase activators Download PDFInfo
- Publication number
- CA2488642C CA2488642C CA2488642A CA2488642A CA2488642C CA 2488642 C CA2488642 C CA 2488642C CA 2488642 A CA2488642 A CA 2488642A CA 2488642 A CA2488642 A CA 2488642A CA 2488642 C CA2488642 C CA 2488642C
- Authority
- CA
- Canada
- Prior art keywords
- compound according
- alkyl
- alkylene
- aryl
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/36—Sulfur atom
- C07D473/38—Sulfur atom attached in position 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2744893A CA2744893A1 (en) | 2002-06-27 | 2003-06-27 | Aryl carbonyl derivatives as glucokinase activators |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200200999 | 2002-06-27 | ||
DKPA200200999 | 2002-06-27 | ||
US39414402P | 2002-07-03 | 2002-07-03 | |
US60/394,144 | 2002-07-03 | ||
DKPA200300286 | 2003-02-25 | ||
DKPA200300286 | 2003-02-25 | ||
US45222803P | 2003-03-05 | 2003-03-05 | |
US60/452,228 | 2003-03-05 | ||
PCT/DK2003/000449 WO2004002481A1 (en) | 2002-06-27 | 2003-06-27 | Aryl carbonyl derivatives as therapeutic agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2744893A Division CA2744893A1 (en) | 2002-06-27 | 2003-06-27 | Aryl carbonyl derivatives as glucokinase activators |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2488642A1 CA2488642A1 (en) | 2004-01-08 |
CA2488642C true CA2488642C (en) | 2011-09-06 |
Family
ID=30003872
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2488642A Expired - Fee Related CA2488642C (en) | 2002-06-27 | 2003-06-27 | Aryl carbonyl derivatives as glucokinase activators |
CA2744893A Abandoned CA2744893A1 (en) | 2002-06-27 | 2003-06-27 | Aryl carbonyl derivatives as glucokinase activators |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2744893A Abandoned CA2744893A1 (en) | 2002-06-27 | 2003-06-27 | Aryl carbonyl derivatives as glucokinase activators |
Country Status (12)
Families Citing this family (181)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
US20030171411A1 (en) * | 2001-12-21 | 2003-09-11 | Kodra Janos Tibor | Amide derivatives as therapeutic agents |
EP1466912B1 (en) | 2002-01-18 | 2013-04-24 | Astellas Pharma Inc. | 2-acylaminothiazole derivative or salt thereof |
KR101116627B1 (ko) * | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
US7799524B2 (en) * | 2002-10-03 | 2010-09-21 | Ecole Polytechnique Ferdeale de Lausanne | Substrates for O6-alkylguanina-DNA alkyltransferase |
EP1549626A1 (en) | 2002-10-03 | 2005-07-06 | Novartis AG | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
EP1615878B1 (en) | 2003-01-14 | 2012-04-04 | Cytokinetics, Inc. | Compounds, compositions and methods of treatment for heart failure |
PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
MXPA05010496A (es) * | 2003-03-28 | 2005-11-16 | Pharmacia & Upjohn Co Llc | Moduladores alostericos positivos del receptor de acetilcolina nicotinico. |
US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
EP1641759B1 (en) * | 2003-07-07 | 2014-03-12 | Merck Patent GmbH | Malonamide derivatives |
US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
WO2005046683A1 (en) | 2003-10-07 | 2005-05-26 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
DE10352067A1 (de) * | 2003-10-23 | 2005-05-25 | Bayer Cropscience Ag | Isopentylcarboxanilide |
US7879760B2 (en) * | 2003-10-23 | 2011-02-01 | Bayer Cropscience Ag | Isopentyl carboxanilides for combating undesired micro-organisms |
AU2004309279B2 (en) | 2003-12-26 | 2010-07-15 | Kyowa Kirin Co., Ltd. | Thiazole derivative |
SI1723128T1 (sl) | 2004-01-06 | 2013-04-30 | Transtech Pharma, Inc. | Heteroaril uree in njihova uporaba kot aktivatorji glukokinaze |
WO2005080359A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Benzamide derivatives and their use as glucokinae activating agents |
CA2560689C (en) | 2004-04-02 | 2011-03-01 | Novartis Ag | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes |
RU2006138426A (ru) | 2004-04-02 | 2008-05-10 | Новартис АГ (CH) | Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой |
DE602005019874D1 (de) * | 2004-05-12 | 2010-04-22 | Bristol Myers Squibb Co | Für die behandlung von thrombotischen leiden geeignete harnstoffantagonisten des p2y1-rezeptors |
US7550499B2 (en) * | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
CA2572455C (en) | 2004-06-04 | 2014-10-28 | Therasense, Inc. | Diabetes care host-client architecture and data management system |
TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
JP2008502658A (ja) * | 2004-06-17 | 2008-01-31 | ノボ ノルディスク アクティーゼルスカブ | 肝臓選択的グルコキナーゼ活性化因子の使用 |
JP5080970B2 (ja) | 2004-06-17 | 2012-11-21 | サイトキネティクス・インコーポレーテッド | 心疾患を治療するための置換尿素誘導体 |
CA2573999A1 (en) | 2004-07-16 | 2006-04-06 | Sunesis Pharmaceuticals, Inc. | Thienopyrimidines useful as aurora kinase inhibitors |
US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
KR20070049655A (ko) | 2004-08-13 | 2007-05-11 | 제넨테크, 인크. | Atp-이용 효소 억제 활성을 나타내는2-아미도-티아졸-기재 화합물과 조성물 및 이들의 용도 |
US7332529B2 (en) * | 2004-10-26 | 2008-02-19 | Carr Andrew J | Thermoreversible organogelators, compositions and methods of making thereof |
WO2006068760A2 (en) | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Anti-inflammatory pyrazolopyrimidines |
CA2590720A1 (en) | 2004-12-03 | 2006-06-08 | Lone Jeppesen | Heteroaromatic glucokinase activators |
WO2006062982A2 (en) * | 2004-12-07 | 2006-06-15 | Locus Pharmaceuticals, Inc. | Urea inhibitors of map kinases |
US7612200B2 (en) * | 2004-12-07 | 2009-11-03 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
MX2007008434A (es) | 2005-01-19 | 2007-07-25 | Squibb Bristol Myers Co | Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos. |
EP1894930A4 (en) | 2005-06-23 | 2010-06-23 | Kyowa Hakko Kirin Co Ltd | THIAZOLE DERIVATIVE |
ATE502924T1 (de) | 2005-06-27 | 2011-04-15 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden |
KR20080027890A (ko) | 2005-06-27 | 2008-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | 혈전성 증상의 치료에 유용한 p2y1 수용체의 n-연결헤테로시클릭 길항제 |
DE602006017694D1 (de) | 2005-06-27 | 2010-12-02 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden |
WO2007002634A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
EP1904438B1 (en) * | 2005-07-08 | 2012-02-29 | Novo Nordisk A/S | Dicycloalkylcarbamoyl ureas as glucokinase activators |
KR20080024211A (ko) | 2005-07-08 | 2008-03-17 | 노보 노르디스크 에이/에스 | 디시클로알킬 우레아 글루코키나제 활성제 |
AU2006268406C1 (en) | 2005-07-09 | 2011-02-24 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
ES2422383T3 (es) * | 2005-07-14 | 2013-09-11 | Novo Nordisk As | Activadores de urea glucoquinasa |
DE102005033103A1 (de) * | 2005-07-15 | 2007-01-25 | Bayer Healthcare Ag | Heterocyclylamid-substituierte Thiazole, Pyrrole und Thiophene |
US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
NZ566877A (en) | 2005-09-29 | 2010-05-28 | Sanofi Aventis | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
GT200600428A (es) | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
JP2009515997A (ja) * | 2005-11-18 | 2009-04-16 | タケダ サン ディエゴ インコーポレイテッド | グルコキナーゼ活性剤 |
US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
EP1959960B1 (en) | 2005-12-15 | 2013-04-10 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
US7718657B2 (en) | 2005-12-16 | 2010-05-18 | Cytokinetics, Inc. | Certain indanyl urea modulators of the cardiac sarcomere |
JP5178526B2 (ja) | 2005-12-19 | 2013-04-10 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
WO2007081690A2 (en) * | 2006-01-04 | 2007-07-19 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
JP5302012B2 (ja) | 2006-03-08 | 2013-10-02 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤 |
US7585868B2 (en) | 2006-04-04 | 2009-09-08 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists |
US8211925B2 (en) | 2006-04-28 | 2012-07-03 | Transtech Pharma, Inc. | Benzamide glucokinase activators |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
WO2007143434A2 (en) | 2006-05-31 | 2007-12-13 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents |
EP2452674B1 (en) * | 2006-08-08 | 2014-03-26 | Akarx, Inc. | Compositions and methods for increasing blood platelet levels in humans |
US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
WO2008047821A1 (fr) * | 2006-10-18 | 2008-04-24 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique fusionné |
CL2007003061A1 (es) | 2006-10-26 | 2008-08-01 | Astrazeneca Ab | Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2. |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US8163779B2 (en) | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
EP2118083A1 (en) * | 2007-01-09 | 2009-11-18 | Novo Nordisk A/S | Urea glucokinase activators |
AU2008204530B2 (en) | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
US8940900B2 (en) | 2007-02-28 | 2015-01-27 | Advinus Therapeutics Private Limited | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
EP2155720B1 (en) | 2007-06-08 | 2013-07-17 | Advinus Therapeutics Private Limited | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
CA2700028A1 (en) * | 2007-09-21 | 2009-04-02 | Sanofi-Aventis | (carboxylalkylenephenyl)phenyloxamides, method for the production thereof and use of same as a medicament |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
WO2009088990A1 (en) | 2008-01-04 | 2009-07-16 | Intellikine, Inc. | Certain chemical entities, compositions and methods |
US8637542B2 (en) * | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
EP2294053B1 (en) | 2008-05-16 | 2016-01-06 | Takeda California, Inc. | Glucokinase activators |
WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
CN102124009B (zh) | 2008-07-08 | 2014-07-23 | 因特利凯公司 | 激酶抑制剂及其使用方法 |
WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
DK2358720T3 (en) | 2008-10-16 | 2016-06-06 | Univ California | Heteroarylkinaseinhibitorer fused-ring |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
GEP20135992B (en) | 2009-01-12 | 2013-12-25 | Icagen Inc | Sulfonamide derivatives |
WO2010129816A2 (en) | 2009-05-07 | 2010-11-11 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
US20110166112A1 (en) * | 2009-08-14 | 2011-07-07 | Eisai, Inc. | Method for stimulating platelet production |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
WO2011080755A1 (en) | 2009-12-29 | 2011-07-07 | Advinus Therapeutics Private Limited | Fused nitrogen heterocyclic compounds, process of preparation and uses thereof |
WO2011095997A1 (en) | 2010-02-08 | 2011-08-11 | Advinus Therapeutics Private Limited | Benzamide compounds as glucokinase activators and their pharmaceutical application |
US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
CN102971313A (zh) | 2010-04-14 | 2013-03-13 | 百时美施贵宝公司 | 新颖的葡糖激酶激活剂及其使用方法 |
MX342288B (es) | 2010-04-22 | 2016-09-23 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
MX347372B (es) | 2010-05-26 | 2017-04-25 | Vtv Therapeutics Llc | Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa. |
US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
EP2402327B1 (en) | 2010-06-29 | 2018-03-07 | Impetis Biosciences Ltd. | Acetamide compounds as glucokinase activators, their process and medicinal applications |
ES2532356T3 (es) | 2010-07-09 | 2015-03-26 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
JP2013544787A (ja) | 2010-10-13 | 2013-12-19 | タケダ カリフォルニア インコーポレイテッド | アザインダゾール誘導体の調製方法 |
EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
SG191040A1 (en) | 2010-12-23 | 2013-08-30 | Pfizer | Glucagon receptor modulators |
NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
PE20140253A1 (es) | 2011-02-08 | 2014-03-09 | Pfizer | Moduladores del receptor de glucagon |
AR085397A1 (es) | 2011-02-23 | 2013-09-25 | Intellikine Inc | Combinacion de inhibidores de quinasa y sus usos |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
TWI565709B (zh) | 2011-07-19 | 2017-01-11 | 英菲尼提製藥股份有限公司 | 雜環化合物及其用途 |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP2734503B1 (en) | 2011-07-22 | 2015-09-16 | Pfizer Inc. | Quinolinyl glucagon receptor modulators |
AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ[3,4−d]ピリミジンおよびその用途 |
EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
ES2583853T3 (es) | 2011-10-03 | 2016-09-22 | Respivert Limited | 1-Pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)ureas como inhibidores de p38 MAP cinasa |
CA2857344C (en) | 2011-12-21 | 2019-02-12 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
SG11201406987UA (en) | 2012-05-17 | 2014-12-30 | Transtech Pharma Llc | Glucokinase activator compositions for the treatment of diabetes |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
SG10201605291WA (en) | 2012-08-28 | 2016-08-30 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
CN104662013A (zh) | 2012-09-26 | 2015-05-27 | 兴和株式会社 | 新型的苯基乙酰胺化合物及含有其的药物 |
SG11201502331RA (en) | 2012-09-26 | 2015-04-29 | Univ California | Modulation of ire1 |
NZ706999A (en) * | 2012-10-15 | 2018-12-21 | Agios Pharmaceuticals Inc | Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof |
HUE034820T2 (en) | 2013-02-28 | 2018-02-28 | Janssen Sciences Ireland Uc | Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B |
DK2970272T3 (en) | 2013-03-14 | 2019-04-23 | Merck Patent Gmbh | glycosidase |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
ES2687481T3 (es) | 2013-03-15 | 2018-10-25 | Chromocell Corporation | Moduladores del canal de sodio para el tratamiento del dolor |
EA027068B1 (ru) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
WO2014184365A1 (en) | 2013-05-17 | 2014-11-20 | Janssen R&D Ireland | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
TR201807090T4 (tr) | 2013-07-25 | 2018-06-21 | Janssen Sciences Ireland Uc | Glioksamid sübstitüeli pirrolamid deriveleri ve bunun hepatitin tedavisine yönelik ilaçlar olarak kullanımı. |
BR112016005271A2 (pt) | 2013-09-10 | 2020-05-12 | Chromocell Corporation | Moduladores de canais de sódio para o tratamento da dor e do diabetes |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EA201690713A1 (ru) | 2013-10-04 | 2016-08-31 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
CA2926950C (en) | 2013-10-10 | 2022-10-11 | Eastern Virginia Medical School | 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase |
WO2015059212A1 (en) | 2013-10-23 | 2015-04-30 | Janssen R&D Ireland | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
AU2015214096B2 (en) | 2014-02-05 | 2021-02-11 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
CN110483484A (zh) | 2014-02-06 | 2019-11-22 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
MX371353B (es) | 2014-02-14 | 2020-01-27 | Respivert Ltd | Compuestos heterociclicos aromaticos como compuestos antiinflamatorios. |
CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
ES2957761T3 (es) | 2014-04-15 | 2024-01-25 | Vertex Pharma | Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
BR112017003658B1 (pt) | 2014-08-28 | 2022-12-06 | Asceneuron Sa | Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びb型肝炎感染症の治療法 |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
NZ740616A (en) | 2015-09-14 | 2023-05-26 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
CA3000197A1 (en) | 2015-09-29 | 2017-04-06 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
TW201733979A (zh) * | 2015-12-11 | 2017-10-01 | Teijin Pharma Ltd | 胺基唑衍生物 |
US11612599B2 (en) | 2016-02-25 | 2023-03-28 | Asceneuron Sa | Glycosidase inhibitors |
JP2019506430A (ja) | 2016-02-25 | 2019-03-07 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
BR112018017225A2 (pt) | 2016-02-25 | 2019-01-15 | Asceneuron Sa | sal de adição de ácido, composto, métodos para preparação de um sal de adição de ácido, para tratamento de uma tauopatia e para inibição de uma glicosidase, e, forma de dosagem oral sólida. |
US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
EP3848026A1 (en) | 2016-04-15 | 2021-07-14 | Novira Therapeutics Inc. | Combinations and methods comprising a capsid assembly inhibitor |
JP6938545B2 (ja) | 2016-05-20 | 2021-09-22 | ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. | ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN109640999A (zh) | 2016-06-24 | 2019-04-16 | 无限药品股份有限公司 | 组合疗法 |
SG10201912376VA (en) | 2016-12-09 | 2020-02-27 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
EA202090871A1 (ru) | 2017-10-06 | 2020-07-03 | Форма Терапьютикс, Инк. | Ингибирование убиквитин-специфической пептидазы 30 |
MA52019A (fr) | 2018-03-14 | 2021-01-20 | Janssen Sciences Ireland Unlimited Co | Schéma posologique de modulateur d'assemblage de capside |
TW202012414A (zh) | 2018-04-12 | 2020-04-01 | 美商拓臻股份有限公司 | 三環ask1抑制劑 |
US11407771B2 (en) * | 2018-05-30 | 2022-08-09 | Washington University | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof |
AU2019287437A1 (en) | 2018-06-12 | 2020-09-10 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
CR20200613A (es) | 2018-06-13 | 2021-06-10 | Xenon Pharmaceuticals Inc | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
AU2019322325B2 (en) | 2018-08-17 | 2022-01-20 | Novartis Ag | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors |
WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
US10981905B2 (en) | 2018-08-31 | 2021-04-20 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
EP4218934A1 (en) | 2018-10-05 | 2023-08-02 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
JP2022521081A (ja) | 2019-02-22 | 2022-04-05 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Hbv感染若しくはhbv誘導性疾患の治療において有用なアミド誘導体 |
CN113795486A (zh) | 2019-05-06 | 2021-12-14 | 爱尔兰詹森科学公司 | 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物 |
AR126868A1 (es) * | 2021-08-25 | 2023-11-22 | Basf Se | Malonamidas herbicidas |
WO2023044364A1 (en) | 2021-09-15 | 2023-03-23 | Enko Chem, Inc. | Protoporphyrinogen oxidase inhibitors |
Family Cites Families (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR7428A (US08063081-20111122-C00242.png) | ||||
US2431801A (en) * | 1944-01-11 | 1947-12-02 | George A Gibson | Pressure compensated thermostat |
GB771147A (en) * | 1954-06-04 | 1957-03-27 | Merck & Co Inc | Derivatives of urea |
US3152136A (en) | 1958-10-30 | 1964-10-06 | Dow Chemical Co | Dinitroaroyl-nu-pyridyl amides |
US3067250A (en) | 1959-01-26 | 1962-12-04 | Dow Chemical Co | 4-aryl, 1, 1-di propynyl-semicarbazides |
US3317534A (en) * | 1963-10-30 | 1967-05-02 | Chugai Pharmaceutical Co Ltd | Benzamidopyrimidines |
US3551442A (en) | 1965-04-06 | 1970-12-29 | Pechiney Saint Gobain | Thiazole derivatives |
ZA6706928B (US08063081-20111122-C00242.png) | 1967-03-23 | |||
CH493195A (de) | 1968-01-23 | 1970-07-15 | Ciba Geigy | Schädlingsbekämpfungsmittel |
GB1195672A (en) | 1968-02-01 | 1970-06-17 | Mobil Oil Corp | Novel Urea Derivatives and Herbicides containing the same |
US4175081A (en) | 1968-02-01 | 1979-11-20 | Mobil Oil Corporation | 5-Substituted thiadiazole ureas |
FR7428M (US08063081-20111122-C00242.png) | 1968-05-06 | 1969-11-12 | ||
CH498859A (de) * | 1968-07-17 | 1970-11-15 | Agripat Sa | Verfahren zur Herstellung von Thiadiazolyl-harnstoffen |
BE754783A (fr) | 1969-08-15 | 1971-02-12 | May & Baker Ltd | Derives thiazolyl a usage herbicide leur preparation et les compositions qui les contiennent |
GB1266769A (US08063081-20111122-C00242.png) | 1969-08-15 | 1972-03-15 | ||
GB1318291A (en) * | 1970-04-15 | 1973-05-23 | Shell Int Research | Carboxamide derivatives and fungicidal compositions containing them |
NL7106557A (US08063081-20111122-C00242.png) | 1970-06-15 | 1971-12-17 | ||
AT297799B (de) | 1970-06-15 | 1972-04-10 | Reichert Optische Werke Ag | Temperaturkompensierte Transistor-Gleichspannungs-Vorverstärkerstufe |
IT960595B (it) | 1971-06-16 | 1973-11-30 | Hispaco Ag | Navetta per tessitura |
US3887709A (en) | 1971-09-16 | 1975-06-03 | Zdzislaw Brzozowski | 2-Pyrazoline-1-carboxamide sulfonamide derivatives useful as hypoglycemic agents |
US3862163A (en) | 1971-10-14 | 1975-01-21 | Schering Ag | Phenoxycarboxylic acid amides |
DE2151766C3 (de) | 1971-10-14 | 1981-03-19 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | N-Thiazolinyl-phenoxycarbonsäureamide |
US3874873A (en) | 1972-03-27 | 1975-04-01 | Fmc Corp | Herbicidal compositions based on 1,2,3-thiadiazol-5-yl ureas |
IE38778B1 (en) | 1973-02-02 | 1978-05-24 | Ciba Geigy | New 1,2,4-benzotriazine derivatives |
JPS5614643B2 (US08063081-20111122-C00242.png) | 1973-07-02 | 1981-04-06 | ||
AR206720A1 (es) | 1974-08-30 | 1976-08-13 | Lilly Co Eli | Procedimiento para la preparacion de novedosas n-2-(6-hidroxibenzotiazolil)-n'-fenil(o fenilo substituido)-ureas |
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
PL106114B1 (pl) | 1976-12-31 | 1979-11-30 | Akad Medyczna | Sposob wytwarzania nowych n-(4-/2-/pirazolo-1-karbonamido/-etylo/-benzenosulfonylo)-mocznikow |
DE2712630A1 (de) * | 1977-03-23 | 1978-09-28 | Bayer Ag | 1,3,4-thiadiazol-2-yl-harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide |
DE2716324A1 (de) | 1977-04-07 | 1978-10-12 | Schering Ag | 1,2,3-thiadiazol-3-in-5-yliden- harnstoffe, verfahren zur herstellung dieser verbindungen sowie diese enthaltende mittel mit wachstumsregulatorischer wirkung fuer pflanzen |
JPS6033109B2 (ja) | 1977-04-28 | 1985-08-01 | 塩野義製薬株式会社 | 尿素誘導体の合成法 |
US4241072A (en) | 1979-01-18 | 1980-12-23 | Merck & Co., Inc. | Substituted ureas and processes for their preparation |
DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
IL72093A0 (en) | 1983-06-20 | 1984-10-31 | Lilly Co Eli | N'-substituted(3-alkyl-5-isothiazolyl)urea derivatives |
US4694004A (en) | 1984-07-09 | 1987-09-15 | Fujisawa Pharmaceutical Co., Ltd. | Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
US4808722A (en) | 1985-10-31 | 1989-02-28 | Fmc Corporation | Pyridinylurea N-oxide compounds and agricultural uses |
JPS6456660A (en) * | 1987-05-11 | 1989-03-03 | Sumitomo Chemical Co | Urea derivative or its salt, production thereof and germicide for agriculture and horticulture containing said derivative or salt thereof as active ingredient |
JPH0453257Y2 (US08063081-20111122-C00242.png) | 1987-09-30 | 1992-12-15 | ||
WO1991004027A1 (en) | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
RU2021258C1 (ru) | 1991-02-28 | 1994-10-15 | Агролинц Агрархемикалиен ГмбХ | Способ получения несимметрично дизамещенных мочевин |
JPH05294935A (ja) | 1991-03-15 | 1993-11-09 | Green Cross Corp:The | アミノピリジン系化合物 |
US5371086A (en) | 1991-03-15 | 1994-12-06 | The Green Cross Corporation | Aminopyridine compounds |
JPH04334374A (ja) | 1991-05-07 | 1992-11-20 | Mitsui Toatsu Chem Inc | N−(2−チアゾリル)尿素誘導体、その製造方法および該化合物を含有する殺虫剤 |
BR9306421A (pt) | 1992-05-28 | 1998-09-15 | Pfizer | Novos derivados n-aril e n-heteroariluréia como inbidores da acilcoenzima a:colesterol aciltransferase (acat) |
JP3176137B2 (ja) | 1992-07-02 | 2001-06-11 | 大正製薬株式会社 | ビウレット誘導体 |
JPH06102611A (ja) | 1992-09-22 | 1994-04-15 | Konica Corp | ハロゲン化銀写真感光材料 |
WO1994014801A1 (en) | 1992-12-29 | 1994-07-07 | Smithkline Beecham Plc | Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists |
GB9302275D0 (en) | 1993-02-05 | 1993-03-24 | Smithkline Beecham Plc | Novel compounds |
US5849769A (en) | 1994-08-24 | 1998-12-15 | Medivir Ab | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection |
US5556969A (en) * | 1994-12-07 | 1996-09-17 | Merck Sharp & Dohme Ltd. | Benzodiazepine derivatives |
US6579314B1 (en) | 1995-03-10 | 2003-06-17 | C.R. Bard, Inc. | Covered stent with encapsulated ends |
WO1996040629A1 (en) | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders |
US5846990A (en) | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
CZ120398A3 (cs) | 1995-09-08 | 1998-12-16 | Novo Nordisk A/S | Použití 2-alkylpyrrolidinových derivátů pro přípravu léčiva pro léčbu diabetu, 2-alkylpyrrolidiné deriváty |
JPH09124620A (ja) | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
GB9526560D0 (en) * | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
CA2241567A1 (en) | 1996-01-17 | 1997-07-24 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
CA2197364A1 (en) | 1996-02-15 | 1997-08-16 | Toshikazu Suzuki | Phenol compound and process for preparing the same |
CA2247286A1 (en) | 1996-02-26 | 1997-08-28 | Hirohiko Hasegawa | Sulfonylureidopyrazole derivatives |
JP2000514041A (ja) | 1996-07-26 | 2000-10-24 | ドクター・レディーズ・リサーチ・ファウンデーション | 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物 |
CA2468374C (en) | 1996-08-30 | 2010-12-21 | Novo-Nordisk A/S | Glp-1 derivatives |
TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
ES2199366T3 (es) | 1996-12-31 | 2004-02-16 | Dr. Reddy's Laboratories Ltd. | Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas. |
US5846985A (en) | 1997-03-05 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
JP2001518069A (ja) | 1997-05-02 | 2001-10-09 | ドクター・レディーズ・リサーチ・ファウンデーション | 低脂質性、抗高血圧性特性を有する新規な抗糖尿病化合物、それらの製造方法及びそれらを含有する薬学的組成物 |
SE9702001D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
JP2003514508A (ja) | 1997-07-01 | 2003-04-15 | ノボ ノルディスク アクティーゼルスカブ | グルカゴン拮抗剤/逆作用剤 |
US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
HUP0003999A3 (en) | 1997-07-16 | 2003-03-28 | Novo Nordisk As | Fused 1,2,4-thiadiazine derivatives, their preparation, their use and pharmaceutical compositions containing them |
US6268384B1 (en) | 1997-08-29 | 2001-07-31 | Vertex Pharmaceuticals Incorporated | Compounds possessing neuronal activity |
TW415942B (en) * | 1997-09-03 | 2000-12-21 | American Home Prod | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents |
US6225346B1 (en) | 1997-10-24 | 2001-05-01 | Sugen, Inc. | Tyrphostin like compounds |
WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
AU744281B2 (en) * | 1997-11-10 | 2002-02-21 | Bristol-Myers Squibb Company | Benzothiazole protein tyrosine kinase inhibitors |
US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
ATE321759T1 (de) | 1997-11-14 | 2006-04-15 | Kowa Co | Neue amidverbindungen und medikamente die diese enthalten |
JP4391597B2 (ja) | 1997-12-02 | 2009-12-24 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 抗糖尿病性、低脂質性及び抗高血圧性を有するチアゾリンジオンとオキサゾリジンジオン誘導体 |
JP4403482B2 (ja) * | 1997-12-22 | 2010-01-27 | バイエル コーポレイション | 置換複素環尿素合成のための中間体およびその製造方法 |
JP4437270B2 (ja) * | 1997-12-22 | 2010-03-24 | バイエル コーポレイション | 置換複素環式尿素を用いたrafキナーゼの阻害 |
AU2108099A (en) | 1998-01-30 | 1999-08-16 | Procept, Inc. | Immunosuppressive agents |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
US6407124B1 (en) * | 1998-06-18 | 2002-06-18 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
AU6190299A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
AU6190199A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
JP2002527520A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物、その製造及び使用 |
JP2002527516A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物、それらの製造及び使用 |
WO2000023416A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
EP1123269A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
CA2348879A1 (en) | 1998-11-02 | 2000-05-11 | Welfide Corporation | Pyrrolidine compound and pharmaceutical use thereof |
WO2000035455A1 (en) | 1998-12-15 | 2000-06-22 | Telik, Inc. | Heteroaryl-aryl ureas as igf-1 receptor antagonists |
CZ20011831A3 (cs) | 1998-12-18 | 2001-10-17 | Novo Nordisk A/S | Kondenzované 1,2,4-thiadiazinové deriváty, jejich příprava a pouľití |
WO2000041121A1 (en) | 1999-01-07 | 2000-07-13 | Ccrewards.Com | Method and arrangement for issuance and management of digital coupons and sales offers |
JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドglp−1アゴニスト |
JP2002534511A (ja) | 1999-01-18 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 置換型イミダゾール、それらの調製及び使用 |
WO2000053591A1 (de) | 1999-03-08 | 2000-09-14 | Bayer Aktiengesellschaft | Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel |
MXPA01009814A (es) | 1999-03-29 | 2002-04-24 | Hoffmann La Roche | Activadores de la glucoquinasa. |
US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
MXPA01010472A (es) | 1999-04-16 | 2002-05-06 | Reddy Research Foundation | Formas polimorficas novedosas de un agente contra la diabetes; procedimiento para su preparacion y composiciones farmaceuticas que las contienen. |
WO2000063191A1 (en) | 1999-04-16 | 2000-10-26 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
AU3957800A (en) | 1999-04-16 | 2000-11-02 | Dr. Reddy's Research Foundation | Crystalline r- guanidines, arginine or (l) -arginine (2(s)) -2- ethoxy -3-(4- (2-(10(h) -phenoxazin -10-yl)ethoxy}phenyl)propanoate |
JP2002542245A (ja) | 1999-04-16 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 置換イミダゾール、それらの製造および使用 |
AU3958100A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
JP2002542237A (ja) | 1999-04-20 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 新規な化合物、それらの製造及び使用 |
JP2002542218A (ja) | 1999-04-20 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 新規な化合物、それらの製造および使用 |
AU3957600A (en) | 1999-04-26 | 2000-11-10 | Boehringer Ingelheim International Gmbh | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
US6503949B1 (en) | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
JP2003503350A (ja) * | 1999-06-30 | 2003-01-28 | 第一製薬株式会社 | Vla−4インヒビター化合物 |
US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
EP1211246B1 (en) * | 1999-09-09 | 2004-02-25 | Kumiai Chemical Industry Co., Ltd. | Pyrimidine derivatives and herbicides containing the same |
US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
AU2001236698A1 (en) * | 2000-02-07 | 2001-08-14 | Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
US6410533B1 (en) | 2000-02-10 | 2002-06-25 | Genzyme Corporation | Antibacterial compounds |
JP3788935B2 (ja) | 2000-05-03 | 2006-06-21 | エフ.ホフマン−ラ ロシュ アーゲー | アルキニルフェニルヘテロ芳香族グルコキナーゼ活性化物質 |
AU2001252270B2 (en) | 2000-05-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
KR100519826B1 (ko) | 2000-05-08 | 2005-10-06 | 에프. 호프만-라 로슈 아게 | 파라-아민 치환된 페닐아미드 글루코키나제 활성화제 |
KR100548901B1 (ko) | 2000-05-08 | 2006-02-02 | 에프. 호프만-라 로슈 아게 | 치환된 페닐아세트아미드 및 그의 글루코키나제활성화제로서의 용도 |
CN1245974C (zh) * | 2000-06-28 | 2006-03-22 | 特瓦制药工业有限公司 | 卡维地洛 |
DK1305301T3 (da) | 2000-07-20 | 2005-10-17 | Hoffmann La Roche | Alpha-acyl- og alpha-heteroatomsubstituerede benzenacetamidglucokinase-aktivatorer |
US6645990B2 (en) * | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
US20020173507A1 (en) * | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
WO2002040444A1 (en) * | 2000-11-17 | 2002-05-23 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
ATE316965T1 (de) * | 2000-12-06 | 2006-02-15 | Hoffmann La Roche | Kondensierte heteroaromatische glucokinaseaktivatoren |
EE200300362A (et) * | 2001-01-31 | 2003-12-15 | Pfizer Products Inc. | PDE4 isosüümide inhibiitoritena kasutatavad tiasolüül-, oksasolüül-, pürrolüül- ja imidasolüülhappeamiidi derivaadid |
UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
DE60208630T2 (de) * | 2001-05-11 | 2006-08-17 | Pfizer Products Inc., Groton | Thiazolderivate und ihre Verwendung als cdk-Inhibitoren |
JP2003021704A (ja) | 2001-07-10 | 2003-01-24 | Nippon Sheet Glass Co Ltd | 一組の屈折率分布型ロッドレンズ及び該レンズを備えたマイクロ化学システム |
JP2004536845A (ja) * | 2001-07-11 | 2004-12-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン媒介疾患の治療方法 |
US6881746B2 (en) | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
US20030171411A1 (en) * | 2001-12-21 | 2003-09-11 | Kodra Janos Tibor | Amide derivatives as therapeutic agents |
US6936629B2 (en) * | 2001-12-21 | 2005-08-30 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
KR101116627B1 (ko) * | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
TW200505894A (en) | 2003-08-08 | 2005-02-16 | Yamanouchi Pharma Co Ltd | Tetrahydro-2H-thiopyran-4-carboxamide derivative |
SI1723128T1 (sl) | 2004-01-06 | 2013-04-30 | Transtech Pharma, Inc. | Heteroaril uree in njihova uporaba kot aktivatorji glukokinaze |
JP4334374B2 (ja) * | 2004-03-05 | 2009-09-30 | 株式会社東芝 | 被ばく線量評価方法、被ばく線量評価システムおよび被ばく線量評価プログラム |
KR20080024211A (ko) | 2005-07-08 | 2008-03-17 | 노보 노르디스크 에이/에스 | 디시클로알킬 우레아 글루코키나제 활성제 |
ES2422383T3 (es) * | 2005-07-14 | 2013-09-11 | Novo Nordisk As | Activadores de urea glucoquinasa |
EP2118083A1 (en) * | 2007-01-09 | 2009-11-18 | Novo Nordisk A/S | Urea glucokinase activators |
AU2008204530B2 (en) * | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
-
2003
- 2003-06-27 KR KR1020047021359A patent/KR101116627B1/ko not_active IP Right Cessation
- 2003-06-27 CA CA2488642A patent/CA2488642C/en not_active Expired - Fee Related
- 2003-06-27 MX MXPA05000130A patent/MXPA05000130A/es active IP Right Grant
- 2003-06-27 PL PL374920A patent/PL215132B1/pl unknown
- 2003-06-27 BR BR0312023-6A patent/BR0312023A/pt not_active Application Discontinuation
- 2003-06-27 JP JP2004548878A patent/JP4881559B2/ja not_active Expired - Fee Related
- 2003-06-27 EP EP11189145A patent/EP2471533A1/en not_active Withdrawn
- 2003-06-27 AU AU2003243921A patent/AU2003243921B2/en not_active Ceased
- 2003-06-27 CA CA2744893A patent/CA2744893A1/en not_active Abandoned
- 2003-06-27 EP EP03761446.8A patent/EP1531815B1/en not_active Expired - Lifetime
- 2003-06-27 WO PCT/DK2003/000449 patent/WO2004002481A1/en active Application Filing
- 2003-10-06 US US10/679,887 patent/US7384967B2/en not_active Expired - Fee Related
-
2004
- 2004-12-02 IL IL165532A patent/IL165532A/en active IP Right Grant
-
2007
- 2007-10-31 US US11/982,248 patent/US7897628B2/en not_active Expired - Lifetime
- 2007-10-31 US US11/981,997 patent/US8063081B2/en not_active Expired - Lifetime
-
2010
- 2010-07-16 JP JP2010162302A patent/JP2010265306A/ja active Pending
-
2011
- 2011-04-18 JP JP2011092035A patent/JP2011168609A/ja not_active Withdrawn
- 2011-07-15 NO NO20111028A patent/NO20111028L/no not_active Application Discontinuation
- 2011-08-15 US US13/209,565 patent/US20110301158A1/en not_active Abandoned
-
2013
- 2013-12-20 US US14/136,825 patent/USRE45670E1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7384967B2 (en) | 2008-06-10 |
EP2471533A1 (en) | 2012-07-04 |
MXPA05000130A (es) | 2005-02-17 |
CA2744893A1 (en) | 2004-01-08 |
US8063081B2 (en) | 2011-11-22 |
AU2003243921B2 (en) | 2009-05-07 |
BR0312023A (pt) | 2005-03-22 |
PL215132B1 (pl) | 2013-10-31 |
NO20111028L (no) | 2005-03-29 |
US7897628B2 (en) | 2011-03-01 |
EP1531815A1 (en) | 2005-05-25 |
US20110301158A1 (en) | 2011-12-08 |
WO2004002481A1 (en) | 2004-01-08 |
CA2488642A1 (en) | 2004-01-08 |
JP2010265306A (ja) | 2010-11-25 |
AU2003243921A1 (en) | 2004-01-19 |
JP2011168609A (ja) | 2011-09-01 |
PL374920A1 (en) | 2005-11-14 |
US20040122235A1 (en) | 2004-06-24 |
KR20050019801A (ko) | 2005-03-03 |
EP1531815B1 (en) | 2014-09-24 |
JP2005537333A (ja) | 2005-12-08 |
IL165532A (en) | 2013-06-27 |
KR101116627B1 (ko) | 2012-10-09 |
US20080119455A1 (en) | 2008-05-22 |
USRE45670E1 (en) | 2015-09-15 |
IL165532A0 (en) | 2006-01-15 |
JP4881559B2 (ja) | 2012-02-22 |
US20080119454A1 (en) | 2008-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2488642C (en) | Aryl carbonyl derivatives as glucokinase activators | |
RU2340605C2 (ru) | Арилкарбонильные производные в качестве терапевтических средств | |
RU2374236C2 (ru) | Амидные производные в качестве активаторов gk | |
EP1904467B1 (en) | Urea glucokinase activators | |
EP1336607A1 (en) | Amide derivatives as glucokinase activators | |
ES2526192T3 (es) | Activadores de la glucocinasa | |
CN101130526B (zh) | 用作治疗剂的芳基羰基衍生物 | |
AU2011265421A1 (en) | Urea glucokinase activators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20200831 |